1. Página Inicial

Programação

Filtrar atividades
BALLROOM
08:00 - 08:10 WELCOME
Rectar Cancer

WELCOME & INTRODUCTION

BALLROOM
08:10 - 09:30 ROUND TABLE
Rectar Cancer

RESURRECTION OF LOCAL EXCISION?

08:10 - 08:22
Is Magnetic resonance useful to select patients for local treatment in early rectal cancer?
08:22 - 08:34
When transanal Local excision for pT1 ALONE is enough? Preliminary data from the TESAR trial & intermuscular dissection
08:34 - 08:46
Chemotherapy and Local Excision for early rectal cancers? The NEO trial.
08:46 - 08:58
GRECCAR 12 – The use of neoadjuvant Folfirinox for organ-preservation
08:58 - 09:10
Local excision after nCRT or TNT? When and how?
09:10 - 09:30
Discussion
BALLROOM
09:30 - 10:00 VIDEO SESSION
Rectar Cancer

SHORT TECHNICAL VIDEO SESSION

09:30 - 09:38
Intermuscular Local excision for early rectal cancer
09:38 - 09:46
Completion TME after initial local excision – is it a nightmare?
09:46 - 10:00
Discussion
BALLROOM
10:00 - 10:30 BREAK
Rectar Cancer

BREAK

BALLROOM
10:30 - 12:00 ROUND TABLE
Rectar Cancer

EARLY / INTERMEDIATE RISK DISTAL RECTAL CANCER – CT2/T3AB N0

10:30 - 10:42
Total Neoadjuvant Therapy for the achievement of a cCR?
10:42 - 10:54
Short-course or Long-course when WW is the goal? The German trial and current data available.
10:54 - 11:06
Long-course RT + Contact radiation leads nearly 90% organ preservation – Why anything else?
11:06 - 11:18
Isn’t TME (without RT or chemotherapy) a better option?
11:18 - 12:00
Discussion
BALLROOM
12:00 - 13:00 SATELLITE SYMPOSIUM
Rectar Cancer

SATELLITE SYMPOSIUM - ADVANCED RECTAL CANCER

12:00 - 12:15
The anatomical landmarks and challenges for each compartment in pelvic exenteration.
12:15 - 12:30
Level of sacral resection – what are the limits?
12:30 - 12:45
The recurrent lateral pelvic node long after TME
12:45 - 13:00
Discussion
BALLROOM
13:00 - 14:00 BREAK
Rectar Cancer

LUNCH BREAK

BALLROOM
14:00 - 15:30 ROUND TABLE
Rectar Cancer

TRIAL UPDATE IN LOCALLY ADVANCED RECTAL CANCER

14:00 - 14:12
PRODIGE – Why FOLFIRINOX should be the new normal in all locally advanced rectal cancer
14:12 - 14:24
PROSPECT – Can we avoid radiation? When and for whom can we eliminate RT?
14:24 - 14:36
OPRA - Is organ-preservation main-stream now? What still needs to be done? Lessons learned from the OPRA trial
14:36 - 14:48
Current status of MSI rectal cancer managed by immunotherapy – Where are we at?
14:48 - 15:00
Elderly and Frail patients with locally advanced disease – How to balance treatment morbidity
15:00 - 15:30
Discussion
BALLROOM
15:30 - 16:00 BREAK
Rectar Cancer

BREAK

BALLROOM
16:00 - 17:00 CASE DISCUSSION
Rectar Cancer

MDT EARLY RECTAL CANCER – FROM ARCHIVES OF HOSPITAL ALEMÃO OSWALDO CRUZ

BALLROOM
17:00 - 18:15 ROUND TABLE
Rectar Cancer

LOCALLY ADVANCED DISEASE

17:00 - 17:12
Radiological Assessment - How nodal staging became less relevant than other radiological features for the decision management in rectal cancer?
17:12 - 17:24
MR quality in rectal cancer – How heterogenous is the quality of MR and how it impacts decision management?
17:24 - 17:36
How tridimensional vascular reconstruction may help surgeon plan/perform rectal cancer surgery
17:36 - 17:48
What about lateral pelvic nodes? Pre or post treatment findings to consider lateral node dissection?
17:48 - 18:15
Discussion
BALLROOM
18:15 - 19:15 BREAK
Rectar Cancer

WELCOME COCKTAIL

BALLROOM
08:00 - 09:10 VIDEO SESSION
Rectar Cancer

VIDEO FORUM

08:00 - 08:10
Retroperitonial approach for the left colon – When you do not want to get into the abdomen…
08:10 - 08:20
Lateral node dissection – the role of ICG
08:20 - 08:30
What is a proper D3 dissection in upper rectal cancer
08:30 - 08:40
Robotic TME – How I do it – step by step
08:40 - 08:50
Combined TME & prostatectomy with the use of robot
08:50 - 09:10
Discussion
BALLROOM
09:10 - 10:00 ROUND TABLE
Rectar Cancer

LATERAL NODE CORNER

09:10 - 09:20
The “perfect” lateral node dissection with the robot – Tips and tricks
09:20 - 09:30
Lateral node in the setting of a complete clinical response
09:30 - 09:40
Lateral node dissection without preoperative treatment – Is there a role? What to do with a patient with a 7mm node in the absence of other high-risk factors?
09:40 - 10:00
Discussion
BALLROOM
10:00 - 10:30 BREAK
Rectar Cancer

BREAK

BALLROOM
10:30 - 12:00 ROUND TABLE
Rectar Cancer

CHALLENGING ANASTOMOSIS IN DISTAL RECTAL CANCER

10:30 - 10:40
When double-stapling is the preferred strategy and new stapling alternatives
10:40 - 10:50
Transrectal transection and single-stapled anastomosis x Pull-through – Choosing one or the other?
10:50 - 11:00
Diversion or no diversion – Who should not be diverted and why?
11:00 - 11:10
Why ICG SHOULD be implemented into routine clinical practice
11:10 - 11:20
Partial mesorectal excision – It’s all about the level of transection…
11:20 - 12:00
Discussion
BALLROOM
12:00 - 13:30 BREAK
Rectar Cancer

LUNCH BREAK

BALLROOM
13:30 - 14:30 ROUND TABLE
Rectar Cancer

ASSESSMENT OF TUMOR RESPONSE AFTER NCRT/TNT

13:30 - 13:42
What happens when mrEMVI+ become ymrEMVI-?
13:42 - 13:54
What is a near-complete clinical response and how to deal with it?
13:54 - 14:06
Local regrowths & the risk of distant metastasis – are we really at risk?
14:06 - 14:30
Discussion
BALLROOM
14:30 - 15:30 CASE DISCUSSION
Rectar Cancer

ARCHIVES FROM HOSPITAL ALEMÃO OSWALDO CRUZ

BALLROOM
15:30 - 16:00 BREAK
Rectar Cancer

BREAK

BALLROOM
16:00 - 17:10 ROUND TABLE
Rectar Cancer

EXCITING VIDEOS – DO NOT TRY THIS AT HOME!

16:00 - 16:10
Robotic TME with synchronous liver metastasis resection
16:10 - 16:20
Management of anastomotic leaks – aggressive transanal approach
16:20 - 16:30
Minimally invasive para-aortic nodal dissection
16:30 - 16:40
Intraoperative bleeding during lateral pelvic node dissection
16:40 - 16:50
Minimally invasive Deloyers Procedure
16:50 - 17:10
Discussion
BALLROOM
17:10 - 18:10 ROUND TABLE
Rectar Cancer

CUTTING EDGE

17:10 - 17:22
Is there a place for Immunotherapy in MSS rectal cancer?
17:22 - 17:34
Can we increase organ-preservation by intensifying treatment? JANUS trial
17:34 - 17:46
ctDNA in rectal cancer – what is the role in adjuvant chemotherapy decision management? Can we extrapolate data from colon cancer?
17:46 - 18:10
Discussion
BALLROOM
18:10 - 19:10 BREAK
Rectar Cancer

ADJOURN